Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere, specifically whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Travere's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3].

SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Shane Kovacs, Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 to pursue new opportunities. Mr. Kovacs will continue in a consulting capacity with Olema through August 1, ...

WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future fin ...

This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic areas such as Endometrial cancer, Colorectal cancer, Weight Management, Acne, and Duchenne muscular dystrophy. Let us unpack the key developments and milestones in the biotech space this week.FDA Approvals & RejectionsIntellia Gets FDA Green Light to Resume MAGNITUDE-2 Phase 3 TrialIntellia Therapeutics, Inc. (NTLA) said the U.S. FDA has lif ...

LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the prestigious 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The accepted paper, titled "Evalua ...

David Novack, President & COO of Dynavax Technologies Corporation (NASDAQ:DVAX), exercised 114,000 stock options and immediately sold the resulting shares for a transaction value of approximately $1.8 million, according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 114,000 Transaction value $1.8 million Post-transaction shares (direct) 63,344 Post-transaction value (direct ownership) ~$989,433.28 Transaction value based on SEC Form 4 weighted av ...

Alumis Inc. (NASDAQ:ALMS) is one of the new stocks on the rise. On January 21, Chardan initiated coverage of Alumis with a Buy rating and a $37 price target driven by the significant potential of the company’s late-stage autoimmune pipeline. The firm’s outlook is driven by envudeucitinib, which is a TYK2 inhibitor that recently met all primary and secondary endpoints in two Phase III trials for moderate-to-severe plaque psoriasis. By showing high statistical significance in skin clearance and patient-repor ...

​Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Gregory Renza from Turist Financial reiterated a Buy rating on the stock and raised the price target from $11 to $13. Earlier on January 23, Soumit Roy from JonesTrading assigned a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) with a $12 price target. ​Analysts from Truist Financial noted that the increase in price target is based on the company’s Q4 2025 pre-report and the firm’s meeting with the co ...

​Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock with a $31 price target. Earlier, on January 14, BTIG reiterated a Buy rating on the stock with a $30 price target. Analysts at BTIG noted that the bullish sentiment follows the company’s recently highlighted key 2026 objectives. Management highlighted that their bexdeg, which is a BTK degrader for relapsed chronic lymp ...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible adult patients, their families and the broader healthcare system due to the current requirement to visit infusion centres or have home infusions every-2-weeks for treatment PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 (GLOBE N ...